Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
A phase 1/2, open-label safety, tolerability, pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK, ROS1 or NTRK1-3 alterations
Protocol ID
TPX-0005-07
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
Relapsed/ refractory
Location
NSW, QLD, WA
Sponsor
Turning Point Therapeutics, Inc
Links
Trial Status
Open
Sites
The Children's Hospital at Westmead
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Perth Children's Hospital
Queensland Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 25 years
International registry ID's
NCT04094610
| Study Title | A phase 1/2 open-label safety tolerability pharmacokinetics and anti-tumour activity study of repotrectinib in paediatric and young adult subjects with advanced or metastatic malignancies harbouring ALK ROS1 or NTRK1-3 alterations |
|---|---|
| Protocol ID | TPX-0005-07 |
| Disease (Sub Disease) | Solid tumours |
| Diagnosis Stage | Relapsed/ refractory |
| Location | NSW / QLD / WA |
| Sponsor | Turning Point Therapeutics, Inc |
| Links | https://clinicaltrials.gov/ct2/show/NCT04094610 |
| Trial Status | Open |
| Trial Open Date | 20/03/2020 |
| Sites | The Children's Hospital at Westmead / Perth Children's Hospital / Queensland Children's Hospital / Sydney Children's Hospital |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 25 years |
| International registry ID's | NCT04094610 |